As the last of the anti-CGRP mAbs to enter the migraine market, Vyepti has seen moderate uptake since its FDA approval.

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...

Lundbeck’s receptor superagonist designed to treat seizures associated with developmental and epileptic encephalopathies ...

(Bloomberg) -- H. Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug ...

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its ...

Lundbeck H AS is engaged in the research, development, manufacture and distribution of pharmaceuticals for brain disorders. It focuses on the treatment of brain disorders such as Alzheimer's ...

VALBY, Denmark, April 4, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension of the PACIFIC trial investigating bexicaserin ...

Lundbeck is a global biopharmaceutical company solely focused on brain disease and restoring brain health. In 2019, Lundbeck acquired Alder BioPharmaceuticals (now Lundbeck Seattle ...

Accepting New Clients. Therapy is a journey that allows a person to become the best version of themselves through building on strengths and challenging beliefs that do not serve them. As a ...